The latest market report published by Credence Research, Inc. “Global Stem Cells Market – Market Growth, Future Prospects, Competitive Analysis, 2017 – 2025,” the global stem cells market was valued at US$ 5,231.7 Mn in 2016, and is expected to reach US$ 13,731.5 Mn by 2025 expanding at a CAGR of 10.50 % from 2017 to 2025.
[Note: Our Free Complimentary Sample Report Accommodate a Brief Introduction To The Synopsis, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology are also Included]
Stem cell therapy will change the medical treatment in the coming decades with a few factors yet to be discussed that have arisen during clinical studies, such as the intersection of the CGMP guidelines with GCPs, and the temperature control factors, where it is easy to transport cells within the research centre, but a problem emerges when transported to different countries. In fact, once the stem cells are delivered to patients participating in clinical trials, health control is of great concern. The ICH recommendations on stem cell therapy need to be updated as they are 20 years old.
In 2016, the adult stem cell segment dominated the market due to key market factors, such as its high compatibility with the human body, low contamination during subculture procedures and the advantages of avoiding ethical issues linked to the use of other human cells. The induced pluripotent stem cell segment will be the fastest growing market for regenerative medicines, drug screening, disease modeling, and organoid production during the 2017-2025 forecast period. In 2016, regenerative medicine dominated the application category due to factors such as rising prevalence of chronic diseases requiring immediate medical intervention and provides pharmaceutical companies with new opportunities by finding the leading candidate and creating innovative drugs.
The drug discovery and development segment will be the fastest-growing market in the 2017-2025 forecast period due to factors such as increasing demand for pharmaceutical giant stem cell technology to minimize the high attrition rate of late-stage drug candidates and develop creative cellular models. In base year 2016, autologous stem cell therapy was the largest market largely due to factors such as no immunological rejection and no need for anesthesia during the transfer of stem cells to the patient. Allogeneic stem cell therapy will be the fastest-growing segment in the 2017-2025 forecast period due to factors such as increasing demand for oncology as it results in graft versus cancer in the host and the donor can donate more white blood cells as needed.
In 2016, North America held the largest revenue share mainly due to factors such as rising prevalence of chronic diseases, enhanced government spending in the research and development facilities studying stem cells therapy and affordable reimbursement scenario. Asia Pacific will be the fastest growing market throughout the forecast period 2017-2025, majorly due to factors such as technological advancement in the extraction and harvesting of stem cells for therapeutic applications and supportive regulatory environment for stem cells product.
Key Market Movements:
Rising prevalence of chronic diseases requiring immediate medical intervention
Technological advancement in the stem cells isolation and harvesting procedures
Supportive regulatory environment for stem cells products
Merger and acquisition between healthcare insurance providers and specialty clinics has made it possible for patients to procure stem cell therapy reimbursement